| Literature DB >> 35864357 |
Charlotta Kuhlefelt1, Pauliina Homsy2, Jussi P Repo3, Tiina Jahkola2, Susanna Kauhanen2.
Abstract
BACKGROUND: Reconstruction of the breast following mastectomy can improve patients' health-related quality of life (HRQL). We aimed to assess HRQL in women after mastectomy and breast reconstruction and to identify differences in HRQL related to the reconstruction method used.Entities:
Mesh:
Year: 2022 PMID: 35864357 PMCID: PMC9529680 DOI: 10.1007/s00268-022-06677-9
Source DB: PubMed Journal: World J Surg ISSN: 0364-2313 Impact factor: 3.282
General characteristics of the study cohort
| Variable | Median (IQR), range |
|---|---|
| Age (years) | 57 (52–63), 30–78 |
| Time from first reconstructive surgery to answering the BREAST-Q (months) | 28 (21–35), 10–174 |
| Time from last operation to answering the BREAST-Q (months) | 16 (10–21), 0.2–38 |
| BMI (kg/m2) | 25 (23–28), 18–34 |
aASA I a normal healthy patient, ASA II a patient with mild systemic disease, ASA III a patient with severe systemic disease
Surgical descriptive of the study cohort
| Variable | Group | ||
|---|---|---|---|
| Type of cancer | DCISa | 23 (16) | |
| Ductal carcinoma | 66 (45) | ||
| LCISb | 2 (1.4) | ||
| Lobular carcinoma | 23 (16) | ||
| Other or undetermined | 12 (8.2) | ||
| Not cancer | 20 (14) | ||
| Bilateral surgery | Yes | 81 (56) | |
| No | 64 (45) | ||
| Contralateral surgery for aesthetic reasons | Reduction mammoplasty | 20 (14) | |
| Mastopexy | 9 (6.2) | ||
| Mastectomy | 1 (0.7) | ||
| None | 116 (71) | ||
| Time of reconstruction | Immediate | 77 (53) | |
| Delayed | 69 (47) | ||
| Primary reconstruction method | LD | 45 (31) | |
| With implant | 3 (6.7) | ||
| Without implant | 42 (93) | ||
| Microvascular flap | 77 (53) | ||
| Abdominal flap | 64 (83) | ||
| Gracilis flap | 13 (17) | ||
| Fat graft | 18 (12) | ||
| Implant | 6 (4.1) | ||
| Total no of reconstructive surgeriesc | 1 | 27 (18) | |
| LD | 9 (20) | ||
| Microvascular flap | 17 (22) | ||
| Implant | 0 (0) | ||
| Fat graft | 1 (5.6) | ||
| 2-3d | 85 (58) | ||
| LD | 25 (56) | ||
| Microvascular flap | 50 (65) | ||
| Implant | 2 (33) | ||
| Fat graft | 8 (44) | ||
| 4–5 | 24 (16) | ||
| LD | 10 (22) | ||
| Microvascular flap | 7 (9.1) | ||
| Implant | 1 (17) | ||
| Fat graft | 6 (33) | ||
| 5 or more | 10 (6.8) | ||
| LD | 1 (2.2) | ||
| Microvascular flap | 3 (3.9) | ||
| Implant | 3 (50) | ||
| Fat graft | 3 (17) | ||
| Clavien-Dindo classificatione | 0 | 81 (55) | |
| LD | 17 (38) | ||
| Microvascular flap | 42 (55) | ||
| Implant | 4 (67) | ||
| Fat graft | 18 (100) | ||
| 1 | 40 (27) | ||
| LD | 22 (49) | ||
| Microvascular flap | 17 (22) | ||
| Implant | 1 (17) | ||
| Fat graft | 0 (0) | ||
| 2 | 3 (2.1) | ||
| LD | 2 (4.4) | ||
| Microvascular flap | 1 (1.3) | ||
| Implant | 0 (0) | ||
| Fat graft | 0 (0) | ||
| 3a | 2 (1.4) | ||
| LD | 1 (2.2) | ||
| Microvascular flap | 0 (0) | ||
| Implant | 1 (17) | ||
| Fat graft | 0 (0) | ||
| 3b | 20 (14) | ||
| LD | 3 (6.7) | ||
| Microvascular flap | 17 (22) | ||
| Implant | 0 (0) | ||
| Fat graft | 0 (0) | ||
| Complications | Prolonged wound care | 13 (8.9) | |
| Seroma | 29 (20) | ||
| Exploration surgery | 2 (1.4) | ||
| Bleeding | 4 (2.7) | ||
| Evacuation of hematoma | 9 (6.2) | ||
| Re-anastomosis | 6 (4.1) | ||
| Primary revision surgery | 7 (4.8) | ||
| Secondary revision surgery | 11 (7.5) | ||
| Scar revision | 14 (9.6) | ||
| Removal of the flap | 2 (1.4) | ||
| Other | 2 (1.4) | ||
| None | 68 (47) | ||
| Reconstruction of the nipple | Yes | 67 (46) | |
| No | 79 (54) | ||
aDuctal carcinoma in situ
bLobular carcinoma in situ
cExcluding nipple reconstructions and surgery due to complications
dSix out of 66 patients had bilateral reconstructions and only one reconstruction surgery per breast
eGrade I: Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics, electrolytes, and physiotherapy. This grade also includes wound infections opened at the bedside. Grade II: Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Grade III: Requiring surgical, endoscopic or radiological intervention. IIIa: Intervention not under general anesthesia. IIIb: Intervention under general anesthesia
Fig. 1BREAST-Q scores for psychosocial and sexual well-being in women 2.3 (0.8–14.3) years after breast reconstruction
Fig. 2BREAST-Q scores for satisfaction with breasts, physical well-being: chest and satisfaction with nipple reconstruction in women 2.3 (0.8–14.3) years after breast reconstruction
Fig. 3BREAST-Q scores for adverse effects of radiation in women 2.3 (0.8–14.3) years after breast reconstruction
Fig. 4BREAST-Q scores for satisfaction with information, satisfaction with surgeon, satisfaction with medical team and satisfaction with office staff in women 2.3 (0.8–14.3) years after breast reconstruction